Chimera Biotec is a service provider for bioanalysis as well as development, validation and support of ultra-sensitive and technically demanding immunoassays. We provide ultra-sensitive GLP/GCP bioanalytical support for all phases of drug discovery and development. For over 20 years, we have specialized in supporting drug development programs with highest demands on bioanalytical quality. Our long standing expertise in beyond ELISA sensitive immunoassays enables us to make the most out of any immunoassay platform. Excellence in immunoassay development, validation and bioanalysis is our core motivation. Beginning with our proprietary Imperacer® (Immuno-PCR) platform, which combines immunoassay specificity with an exponential real-time qPCR read-out, Chimera offers services on several highly sensitive platforms that go beyond the capabilities of conventional ELISA. We also provide Simoa® (Quanterix), MSD and high sensitivity ELISA. There is no need to invest in costly laboratory equipment. Continue working on your preferred in-house platform and only outsource case studies where improved sensitivities or related performance criteria is a must. Starting from your antibody experience on your platform, we can run a technology evaluation study on our ultra-sensitive platforms and – together with you – select the ideal platform for your study. Whether you are looking for non-regulated discovery phase/GCP clinical phase support or IND-enabling TOX under full GLP-regime, we will ensure that immunoassay method validation is tailored to your expectations of bioanalytical support. From high dosing in TOX through extreme low dosing in dose-escalation to later clinical stages, we provide regulated PK/PD sample testing using validated methods based on the same assay.